Kelun Pharmaceutical's SKB107 clinical trial approved
Sichuan Kelun Pharmaceutical (SZSE:002422) announced that its subsidiary, Kelun-Biotech, has received approval from the National Medical Products Administration for the clinical trial application of SKB107, a radionuclide drug conjugate (RDC). SKB107, previously known as TBM-001, is being developed jointly with the Affiliated Hospital of Southwest Medical University, following an exclusive licensing agreement announced in September 2023. The drug is designed for the treatment of advanced solid tumor bone metastases. While this regulatory milestone has been achieved, Kelun reminds investors that drug development is lengthy and subject to uncertainty, advising caution when making investment decisions.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sichuan Kelun Pharmaceutical publishes news
Free account required • Unsubscribe anytime